LeadArtis is an Associated Company to the Immunotherapy Network

21-11-2011

The Immunotherapy Network IMMUNONET is a project approved under the Programme of Territorial Cooperation of the European Southwest Area (SUDOE-Interreg IV B). Bringing together leading international scientists, a stable team of cutting-edge research in Immunotherapy has been established in the southwestern Europe.

Leadartis present at the 5th edition of the Healthcare Investment, Forum Conference on November 3, 2011

04-11-2011

This past 3 November, the Medical Association of Barcelona (COMB) hosted the fifth edition of the Healthcare Investment Forum, a conference which aims to make private funding more accessible to companies in the healthcare sector that are in the growth phase and require an injection of up to 3 million euros of capital. Leadartis was one of the 11 companies selected, from more than 30 candidates, to present the project to more than 100 venture investors.

The CDTI has awarded Leadartis with a NEOTEC loan

01-09-2010

The Center for Industrial Technological Development (www.cdti.es), a Spanish governmental body dependent on the Ministry of Science and Innovation has granted a NEOTEC loan to Leadartis for the development of diagnostic and therapeutic candidates.

Leadartis is part of the Genoma España´s Technology Portfolio

01-02-2008

In 2008 LeadArtis signed an agreement with Genoma España, and it has been incorporated to its Technology Portfolio (www.gen-es.com.es). The agreement supported the creation of the company and represented an infusion of resources to finance LeadArtis´start-up activities.

Syndicate content

Latest News

Leadartis reaches a major milestone with the demonstration of absence of toxicity of its drug candidate in preclinical models
13-01-2021

Leadartis reaches a major milestone with the demonstration of...

Leadartis featured in EXPANSION as a ‘Start up’ that leads the fight against cancer
10-11-2020

...

Leadartis closes the investment round in 14 days with an overfunding of 25%
28-09-2020

We are pleased to inform you that the investment round has been successfully closed, raising a...